Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAVIER ALONSO-LLAMAZARES

Allopathic & Osteopathic Physicians Dermatology

NPI
1356315485
CMS profile
151705
Location
CORAL GABLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$146,903.79

337 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAVIER ALONSO-LLAMAZARES

NPI 1356315485 · CMS profile ID 151705

Allopathic & Osteopathic Physicians / Dermatology

CORAL GABLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356315485?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAVIER ALONSO-LLAMAZARES, NPI 1356315485, CMS profile ID 151705. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356315485?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAVIER ALONSO-LLAMAZARES, NPI 1356315485, CMS profile ID 151705. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356315485?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAVIER ALONSO-LLAMAZARES, NPI 1356315485, CMS profile ID 151705, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356315485?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

337 matching records · $146,903.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 337 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 337.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $480.0610/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657887139 CMS
Lilly USA, LLC $80.0010/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657887165 CMS
Lilly USA, LLC $19.2610/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657890761 CMS
Lilly USA, LLC $14.4010/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657890763 CMS
Regeneron Healthcare Solutions, Inc. $28.4610/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673327169 CMS
Lilly USA, LLC $2.1710/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657870103 CMS
Lilly USA, LLC $9.9910/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657870105 CMS
Lilly USA, LLC $1.2810/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657873537 CMS
Lilly USA, LLC $288.0210/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657877007 CMS
Lilly USA, LLC $4.2510/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657877047 CMS
Lilly USA, LLC $17.0010/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657880437 CMS
Lilly USA, LLC $4.2510/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657880439 CMS
Lilly USA, LLC $7.2310/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657880441 CMS
Lilly USA, LLC $1.2810/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657880443 CMS
Lilly USA, LLC $17.0010/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657880445 CMS
Lilly USA, LLC $6.3810/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657883895 CMS
Lilly USA, LLC $28.9010/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657883897 CMS
Lilly USA, LLC $3.0010/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657883899 CMS
Lilly USA, LLC $39.9510/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657883901 CMS
Lilly USA, LLC $1.9110/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657887167 CMS
Lilly USA, LLC $25.5010/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657887169 CMS
Genentech USA, Inc. $16.5510/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681397999 CMS
Novartis Pharmaceuticals Corporation $115.5910/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658972987 CMS
Eli Lilly Export S.A. Puerto Rico Branch $2,800.0010/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657870063 CMS
Eli Lilly Export S.A. Puerto Rico Branch $2,450.0010/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657877013 CMS
Eli Lilly Export S.A. Puerto Rico Branch $2,800.0010/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657880407 CMS
Merz North America, Inc. $139.6810/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689352867 CMS
UCB, Inc. $18.1310/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688241593 CMS
UCB, Inc. $20.6610/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688241595 CMS
UCB, Inc. $2,500.0010/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688241597 CMS
Lilly USA, LLC $97.4810/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657887137 CMS
Eli Lilly Export S.A. Puerto Rico Branch $16.5910/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657877015 CMS
Lilly USA, LLC $89.6810/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657873535 CMS
Lilly USA, LLC $254.0010/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657877011 CMS
Lilly USA, LLC $284.4010/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657880403 CMS
Lilly USA, LLC $10.7610/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657887163 CMS
Lilly USA, LLC $254.0010/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657894073 CMS
Lilly USA, LLC $97.4810/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657870061 CMS
Lilly USA, LLC $395.3510/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657877009 CMS
Encore Dermatology Inc. $21.4810/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698862979 CMS
Celgene Corporation $2.3110/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672943979 CMS
Mayne Pharma Inc. $32.5310/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705486431 CMS
UCB, Inc. $125.0010/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688240381 CMS
UCB, Inc. $10.4410/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688240189 CMS
UCB, Inc. $2,500.0010/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688240191 CMS
UCB, Inc. $4.0010/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688240193 CMS
Novartis Pharmaceuticals Corporation $22.7510/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658972980 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.0010/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684565759 CMS
Encore Dermatology Inc. $8.4910/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698862975 CMS
Merck Sharp & Dohme Corporation $14.2509/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695798811 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $146,903.79 337
PY2020 $40,959.85 114
PY2021 $65,274.67 199
PY2022 $57,719.73 175
PY2023 $141,971.45 290
PY2024 $127,651.34 304
PY2025 $273,856.50 447

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,474,839.08 162
PY2024 Recipient $2,676.00 1
PY2024 Principal investigator $1,733,600.42 298
PY2023 Recipient $11,536.01 2
PY2023 Principal investigator $477,143.57 62
PY2022 Principal investigator $199,921.00 14
PY2021 Principal investigator $952.00 1
PY2020 Recipient $3,381.00 2
PY2020 Principal investigator $3,482.66 5
PY2019 Recipient $76.41 1
PY2019 Principal investigator $854,916.93 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

162 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $13,365.00 12/25/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418528
Principal investigator 1 Incyte Corporation $2,257.20 12/19/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530915
Principal investigator 1 Incyte Corporation $3,594.60 12/19/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530928
Principal investigator 1 Janssen Research & Development, LLC $5,151.00 12/19/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418443
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,338.40 12/18/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431600
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,425.00 12/16/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223289724
Principal investigator 1 Incyte Corporation $1,011.60 12/11/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530944
Principal investigator 1 ABBVIE INC. $1,939.50 12/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202528386
Principal investigator 1 Incyte Corporation $1,000.00 12/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240530906
Principal investigator 1 Incyte Corporation $5,000.00 12/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240530910
Principal investigator 1 Incyte Corporation $818.10 12/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530919
Principal investigator 1 Incyte Corporation $5,282.60 12/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530924
Principal investigator 1 Incyte Corporation $9,527.80 12/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530932
Principal investigator 1 Incyte Corporation $6,000.00 12/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530936
Principal investigator 1 Incyte Corporation $5,213.20 12/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530940
Principal investigator 1 Janssen Research & Development, LLC $17,790.00 12/01/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418520
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,476.90 12/01/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289059
Principal investigator 1 ABBVIE INC. $19,397.40 11/25/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202525216
Principal investigator 1 Incyte Corporation $3,150.00 11/25/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530885
Principal investigator 1 Incyte Corporation $240.00 11/25/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530889
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 11/24/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418439
Principal investigator 1 Janssen Research & Development, LLC $14,056.00 11/24/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418449
Principal investigator 1 Janssen Research & Development, LLC $2,585.00 11/24/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418454
Principal investigator 1 ABBVIE INC. $1,500.00 11/20/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202525042
Principal investigator 1 Incyte Corporation $1,290.60 11/20/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530898
Principal investigator 1 Incyte Corporation $4,723.20 11/14/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530902
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,527.00 11/13/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431598
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,700.00 11/12/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223288213
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,549.74 11/12/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223288281
Principal investigator 1 Novartis Pharmaceuticals Corporation $99,284.12 11/10/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190311115
Principal investigator 1 Incyte Corporation $1,285.20 11/07/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530894
Principal investigator 1 ABBVIE INC. $1,784.70 11/05/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202523097
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,475.00 11/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223287933
Principal investigator 1 Janssen Research & Development, LLC $1,577.00 11/03/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418465
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,061.29 10/30/2025 Non-covered Recipient Entity
Driven Research Llc
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235997659
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 10/28/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223287677
Principal investigator 1 Janssen Research & Development, LLC $15,325.00 10/24/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418537
Principal investigator 1 Incyte Corporation $1,290.60 10/23/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530872
Principal investigator 1 Incyte Corporation $273.60 10/23/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530880
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,833.35 10/23/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431594
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,857.80 10/23/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431596
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,400.00 10/22/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287287
Principal investigator 1 ABBVIE INC. $3,127.50 10/09/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515863
Principal investigator 1 Incyte Corporation $3,122.10 10/09/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530876
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,431.10 10/09/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431592
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,148.30 10/01/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286075
Principal investigator 1 Janssen Research & Development, LLC $3,154.00 09/29/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418515
Principal investigator 1 Janssen Research & Development, LLC $11,805.00 09/29/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418549
Principal investigator 1 Incyte Corporation $1,558.80 09/23/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530863
Principal investigator 1 Incyte Corporation $1,448.10 09/23/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530867
Principal investigator 1 Incyte Corporation $2,422.80 09/18/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530848
Principal investigator 1 Incyte Corporation $3,483.00 09/18/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,064.40 09/18/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223285702
Principal investigator 1 Incyte Corporation $2,108.70 09/12/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530855
Principal investigator 1 Janssen Research & Development, LLC $21,615.00 09/08/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418458
Principal investigator 1 ABBVIE INC. $4,575.70 09/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509610
Principal investigator 1 Incyte Corporation $2,738.70 09/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530858
Principal investigator 1 SANOFI US SERVICES INC. $4,851.60 09/03/2025 Non-covered Recipient Entity
Driven Research Llc
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226081317
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,599.60 09/03/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285067
Principal investigator 1 Incyte Corporation $927.90 08/26/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530843
Principal investigator 1 Janssen Research & Development, LLC $4,774.00 08/25/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418484
Principal investigator 1 Incyte Corporation $4,763.70 08/21/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,556.65 08/19/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223284369
Principal investigator 1 Incyte Corporation $1,741.50 08/14/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530833
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,510.75 08/13/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431590
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,595.25 08/12/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431586
Principal investigator 1 Incyte Corporation $3,106.80 08/07/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530835
Principal investigator 1 Incyte Corporation $1,097.10 08/07/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530840
Principal investigator 1 ABBVIE INC. $3,282.30 08/06/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502326
Principal investigator 1 Janssen Research & Development, LLC $4,774.00 08/01/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418496
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,594.30 08/01/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283725
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,028.90 08/01/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283727
Principal investigator 1 Janssen Research & Development, LLC $3,300.00 07/28/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175188994
Principal investigator 1 Janssen Research & Development, LLC $47,360.00 07/28/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418490
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,500.00 07/25/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431588
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,500.00 07/18/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282856
Principal investigator 1 Incyte Corporation $380.70 07/17/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,891.60 07/17/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223282788
Principal investigator 1 Incyte Corporation $3,109.50 07/10/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530814
Principal investigator 1 Incyte Corporation $1,878.30 07/10/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530818
Principal investigator 1 ABBVIE INC. $3,929.60 07/08/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497028
Principal investigator 1 Incyte Corporation $2,422.80 07/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530822
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,272.40 07/02/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282166
Principal investigator 1 Janssen Research & Development, LLC $13,489.00 06/27/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418477
Principal investigator 1 Incyte Corporation $380.70 06/24/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530791
Principal investigator 1 Janssen Research & Development, LLC $30,320.00 06/23/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418434
Principal investigator 1 Incyte Corporation $2,514.60 06/19/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,152.90 06/13/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281260
Principal investigator 1 Incyte Corporation $4,397.40 06/12/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530801
Principal investigator 1 Incyte Corporation $77.40 06/12/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530809
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,272.40 06/06/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280884
Principal investigator 1 Incyte Corporation $2,669.40 06/05/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530795
Principal investigator 1 Incyte Corporation $1,448.10 06/05/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530805
Principal investigator 1 Janssen Research & Development, LLC $156.00 06/04/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175188921
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/04/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175188941
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/04/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175188965
Principal investigator 1 Janssen Research & Development, LLC $291.00 06/04/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189233
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/04/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189251
Principal investigator 1 ABBVIE INC. $5,272.40 06/03/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202488261
Principal investigator 1 Incyte Corporation $5,049.90 05/28/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530779
Principal investigator 1 Eli Lilly and Company $23,705.00 05/21/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187882376
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,060.00 05/21/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280100
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,272.00 05/20/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223279968
Principal investigator 1 Janssen Research & Development, LLC $8,000.00 05/19/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418471
Principal investigator 1 Janssen Research & Development, LLC $3,101.00 05/15/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175188930
Principal investigator 1 Incyte Corporation $2,975.40 05/08/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530783
Principal investigator 1 ABBVIE INC. $4,106.40 05/07/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482501
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,561.25 05/01/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223278788
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,404.60 05/01/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278796
Principal investigator 1 Incyte Corporation $1,000.00 04/28/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530762
Principal investigator 1 Incyte Corporation $20,737.80 04/28/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530766
Principal investigator 1 Incyte Corporation $6,000.00 04/28/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240530770
Principal investigator 1 Incyte Corporation $1,939.50 04/28/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530775
Principal investigator 1 Janssen Research & Development, LLC $3,101.00 04/28/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175189060
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 04/28/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189069
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 04/28/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189165
Principal investigator 1 Janssen Research & Development, LLC $9,832.00 04/25/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418501
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,520.00 04/24/2025 Non-covered Recipient Entity
Driven Research LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431584
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 04/21/2025 Non-covered Recipient Entity
Driven Research Llc
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226081258
Principal investigator 1 Incyte Corporation $820.80 04/15/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530758
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $950.26 04/11/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277974
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,320.90 04/11/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278014
Principal investigator 1 Incyte Corporation $3,914.80 04/08/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530754
Principal investigator 1 Eli Lilly and Company $4,035.00 04/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187881374
Principal investigator 1 ABBVIE INC. $2,763.60 04/03/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202472868
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,787.45 03/25/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277017
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 03/24/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189053
Principal investigator 1 Incyte Corporation $2,460.00 03/14/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530746
Principal investigator 1 Incyte Corporation $1,664.10 03/11/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530741
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,506.00 03/11/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223276187
Principal investigator 1 ABBVIE INC. $5,272.40 03/07/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202460678
Principal investigator 1 Incyte Corporation $7,521.30 03/04/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530750
Principal investigator 1 Janssen Research & Development, LLC $9,383.00 03/03/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175189110
Principal investigator 1 Janssen Research & Development, LLC $3,646.00 03/03/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418507
Principal investigator 1 Janssen Research & Development, LLC $3,556.00 02/27/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175188989
Principal investigator 1 Janssen Research & Development, LLC $3,556.00 02/27/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189180
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,841.40 02/26/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275619
Principal investigator 1 Incyte Corporation $9,047.80 02/25/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530958
Principal investigator 1 SANOFI US SERVICES INC. $24,288.00 02/24/2025 Non-covered Recipient Entity
Driven Research Llc
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226081249
Principal investigator 1 SANOFI US SERVICES INC. $7,451.60 02/24/2025 Non-covered Recipient Entity
Driven Research Llc
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226081253
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,425.00 02/21/2025 Non-covered Recipient Entity
Driven Research Llc
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis No dispute reported 06/30/2026 1235997657
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,844.75 02/20/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275425
Principal investigator 1 ABBVIE INC. $2,940.40 02/06/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202447943
Principal investigator 1 Janssen Research & Development, LLC $18,296.00 02/06/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418542
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $29,486.60 02/03/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274643
Principal investigator 1 Eli Lilly and Company $819.01 01/31/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187879871
Principal investigator 1 ABBVIE INC. $134.64 01/30/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202443126
Principal investigator 1 Eli Lilly and Company $212,746.04 01/29/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187881372
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 01/29/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175188914
Principal investigator 1 Janssen Research & Development, LLC $1,318.00 01/29/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175188949
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 01/29/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189046
Principal investigator 1 Janssen Research & Development, LLC $1,318.00 01/29/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189172
Principal investigator 1 Janssen Research & Development, LLC $3,556.00 01/29/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189197
Principal investigator 1 Amgen Inc. $35,089.23 01/27/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640873
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 01/24/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175188972
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 01/24/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175188981
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 01/24/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189211
Principal investigator 1 Incyte Corporation $1,548.00 01/17/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530949
Principal investigator 1 Janssen Research & Development, LLC $12,484.00 01/16/2025 Non-covered Recipient Entity
Driven Rsrch Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175189029
Principal investigator 1 Eli Lilly and Company $28,931.00 01/07/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187880857
Principal investigator 1 Incyte Corporation $273.60 01/07/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240530953
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,831.80 01/07/2025 Non-covered Recipient Entity
DRIVEN RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273681